I am not sure about the source of that resume, but it might potentially get Dr.Xu into some troubles:)
Dr. Xu was a student/postdoc in David Scheinberg's lab at Cornell/Sloan
Kettering, but I don't think he ever got a faculty position there. Dr.Xu might have made some contribution to the CD33 projects, his main work was about the regulation of CD13/aminopeptidase N.
While David's work has pushed Lintuzumab (humanized monoclonal antibody
against CD33) into several clinical tests, trials for AML were abandoned in 2010 when a phase IIb trial failed to show increased survival. There is another trial going on for lintuzumab in conjunction with bortezomib as a treatment of myelodysplastic syndromes.
As far as I know, the first monoclonal antibody against CD33 that got
approved by the FDA for treating leukemia is Gemtuzumab ozogamicin (marketed by Wyeth as Mylotarg), a monoclonal antibody to CD33 linked to a cytotoxic agent from the class of calicheamicins. To the best of my knowledge, the drug was developed at the Fred Hutchinson Cancer Research Center and I don't think Dr.Xu was involved in that project. Mylotarg was approved by the FDA in 2000 for use mainly in AML patients over the age of 60. Unfortunately it has brought up many serious safety concerns, and Pfizer had to withdraw the drug from market last year at FDA's request when a clinical trial showed "the drug increased patient death and added no benefit over conventional cancer therapies".
